# Modified against standard DHAP salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma (Lahore)

Source: https://onco.cc/trials/nct07739654/  
OnCo record `nct07739654` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Lahore trial testing whether splitting two chemotherapy drugs into smaller doses over two days works as well for lymphoma that has come back, with less harm to the kidneys and without a hospital stay.

## Summary

Randomised phase 3 trial at Mayo Hospital, Lahore, sponsored by King Edward Medical University (principal investigator Abbas Khokhar). 74 adults with relapsed or refractory diffuse large B-cell lymphoma are randomised 1:1 to modified DHAP (dexamethasone 40 mg days 1 to 4, cisplatin 50 mg/m2 over 6 hours days 1 and 2, cytarabine 2 g/m2 over 3 hours days 1 and 2) or standard DHAP (dexamethasone 40 mg days 1 to 4, cisplatin 100 mg/m2 by 24-hour infusion day 1, cytarabine 2 x 2 g/m2 day 2). The primary endpoint is overall response rate by RECIL 2017; secondary endpoints are progression-free survival, toxicity by CTCAE and quality of life by EORTC QLQ-C30. Primary completion is estimated for 20 May 2027. No results are posted.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Registry id: NCT07739654
- Phase: 3
- Setting: Comparison of Effectiveness and Toxicities of Modified DHAP Protocol With Standard DHAP Protocol in Patients With Relapsed/Refractory Diffused Large B-cell Lymphoma
- Sponsor: King Edward Medical University
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT07739654: https://clinicaltrials.gov/study/NCT07739654

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/)
- institutions: [King Edward Medical University and Mayo Hospital, Lahore](https://onco.cc/institutions/kemu-lahore/)

---
JSON: https://onco.cc/api/v1/entities/nct07739654.json